Vaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 2,250 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the sale, the chief operating officer owned 156,760 shares in the company, valued at $8,830,290.80. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total value of $111,420.00.
• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total transaction of $127,867.50.

Vaxcyte Stock Up 1.1%

NASDAQ:PCVX opened at $57.60 on Tuesday. The company has a market cap of $8.32 billion, a P/E ratio of -8.37 and a beta of 1.22. The firm’s 50 day moving average is $52.21 and its two-hundred day moving average is $53.47. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period last year, the firm earned ($1.04) earnings per share. Research analysts forecast that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Institutional Trading of Vaxcyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new stake in Vaxcyte during the first quarter valued at approximately $58,000. Finally, Allworth Financial LP lifted its holdings in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on PCVX shares. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.